Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT, page-74

I think the best way to look at how PD1vaxx has performed is this. These 12 patients are already on their way to death door. Without it, all of them would be either dead or near death. But with the intervention of PD1vaxx, 9 of them have the progress of this deadly disease stopped in its track. More importantly, this is achieved without the medication adding any health burden on the patients, ie non toxic. After all, what is the point of just surviving if the medication is going to add to ones sufferings!

All in all, PD1vaxx works. But even more importantly now, it is the second B cell candidate that proves the B cell technology works. And they work without adding any toxicity to the patient. AND, there is currently none like it anywhere in the world. Currently, any drugs that do work comes with a price in toxicity and tolerability. And they also come with a high price in dollar term.

So in conclusion, both Hervaxx and PD1vaxx works. They are cheap to produce and they do not add toxicity to the patients. All very fine characteristics of what medicine should do.